Novel approach to recognition of predicted HIV-1 Gag B*3501-restricted CD8 T-cell epitopes by HLA-B*3501+ patients: Confirmation by quantitative ELISpot analyses and characterisation using multimers

Journal of Immunological Methods

Volumn 341, Issue 1-2, 2009, Pages 76-85

  Westrop, Samantha J ^a   Grageda, Nathali ^a   Imami, Nesrina ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

HIV 1; MHC peptide binding; Peptide libraries; T cell epitopes

Indexed keywords

CD8 ANTIGEN; HISTIDYLPROLYLVALYLHISTIDYLALANYLGLYCYLPROLYLISOLEUCYLALANINE; HLA B ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; TYROSYLPROLYLLEUCYLTHREONYLSERYLLEUCYLARGINYLSERYLLEUCINE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPATHOGENESIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL;

AIDS VACCINES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HLA-B ANTIGENS; HUMANS; IMMUNOASSAY; MALE; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 59249103435     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2008.11.003     Document Type: Article

References (52)

1. Allen T.M., Altfeld M., Yu X.G., O'Sullivan K.M., Lichterfeld M., Le Gall S., John M., Mothe B.R., Lee P.K., Kalife E.T., Cohen D.E., Freedberg K.A., Strick D.A., Johnston M.N., Sette A., Rosenberg E.S., Mallal S.A., Goulder P.J., Brander C., and Walker B.D. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J. Virol. 78 (2004) 7069
2. Appay V., Douek D.C., and Price D.A. CD8+ T cell efficacy in vaccination and disease. Nat. Med. 14 (2008) 623
3. Arguello J.R., Little A.M., Pay A.L., Gallardo D., Rojas I., Marsh S.G., Goldman J.M., and Madrigal J.A. Mutation detection and typing of polymorphic loci through double-strand conformation analysis. Nat. Genet. 18 (1998) 192
4. Betts M.R., Price D.A., Brenchley J.M., Lore K., Guenaga F.J., Smed-Sorensen A., Ambrozak D.R., Migueles S.A., Connors M., Roederer M., Douek D.C., and Koup R.A. The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J. Immunol. 172 (2004) 6407
5. Brennan R.M., Miles J.J., Silins S.L., Bell M.J., Burrows J.M., and Burrows S.R. Predictable alphabeta T-cell receptor selection toward an HLA-B*3501-restricted human cytomegalovirus epitope. J. Virol. 81 (2007) 7269
6. Burrows J.M., Wynn K.K., Tynan F.E., Archbold J., Miles J.J., Bell M.J., Brennan R.M., Walker S., McCluskey J., Rossjohn J., Khanna R., and Burrows S.R. The impact of HLA-B micropolymorphism outside primary peptide anchor pockets on the CTL response to CMV. Eur. J. Immunol. 37 (2007) 946
7. Burrows J.M., Bell M.J., Brennan R., Miles J.J., Khanna R., and Burrows S.R. Preferential binding of unusually long peptides to MHC class I and its influence on the selection of target peptides for T cell recognition. Mol. Immunol. 45 (2008) 1818
8. Burton C.T., Gotch F., and Imami N. Rapid qualitative and quantitative analysis of T-cell responses in HIV-1-infected individuals receiving successful HAART and HIV-1 sero-negative controls: concomitant assessment of perforin, IFN-γ and IL-4 Secretion. J. Immunol. Methods 308 (2006) 216
9. Campanelli R., Palermo B., Garbelli S., Mantovani S., Lucchi P., Necker A., Lantelme E., and Giachino C. Human CD8 co-receptor is strictly involved in MHC-peptide tetramer-TCR binding and T cell activation. Int. Immunol. 14 (2002) 39
10. Cao K., Hollenbach J., Shi X., Shi W., Chopek M., and Fernandez-Vina M.A. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum. Immunol. 62 (2001) 1009
11. Carrington M., Nelson G.W., Martin M.P., Kissner T., Vlahov D., Goedert J.J., Kaslow R., Buchbinder S., Hoots K., and O'Brien S.J. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283 (1999) 1748
12. Champagne P., Ogg G.S., King A.S., Knabenhans C., Ellefsen K., Nobile M., Appay V., Rizzardi G.P., Fleury S., Lipp M., Forster R., Rowland-Jones S., Sekaly R.P., McMichael A.J., and Pantaleo G. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410 (2001) 106
13. Deeks S.G., and Walker B.D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27 (2007) 406
14. Dion M.L., Poulin J.F., Bordi R., Sylvestre M., Corsini R., Kettaf N., Dalloul A., Boulassel M.R., Debre P., Routy J.P., Grossman Z., Sekaly R.P., and Cheynier R. HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation. Immunity 21 (2004) 757
15. Douek D.C., McFarland R.D., Keiser P.H., Gage E.A., Massey J.M., Haynes B.F., Polis M.A., Haase A.T., Feinberg M.B., Sullivan J.L., Jamieson B.D., Zack J.A., Picker L.J., and Koup R.A. Changes in thymic function with age and during the treatment of HIV infection. Nature 396 (1998) 690
16. Dzutsev A.H., Belyakov I.M., Isakov D.V., Margulies D.H., and Berzofsky J.A. Avidity of CD8 T cells sharpens immunodominance. Int. Immunol. 19 (2007) 497
17. Effros R.B., and Pawelec G. Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion?. Immunol. Today 18 (1997) 450
18. Fellay J., Shianna K.V., Ge D., Colombo S., Ledergerber B., Weale M., Zhang K., Gumbs C., Castagna A., Cossarizza A., Cozzi-Lepri A., De Luca A., Easterbrook P., Francioli P., Mallal S., Martinez-Picado J., Miro J.M., Obel N., Smith J.P., Wyniger J., Descombes P., Antonarakis S.E., Letvin N.L., McMichael A.J., Haynes B.F., Telenti A., and Goldstein D.B. A whole-genome association study of major determinants for host control of HIV-1. Science 317 (2007) 944
19. Frahm N., Yusim K., Suscovich T.J., Adams S., Sidney J., Hraber P., Hewitt H.S., Linde C.H., Kavanagh D.G., Woodberry T., Henry L.M., Faircloth K., Listgarten J., Kadie C., Jojic N., Sango K., Brown N.V., Pae E., Zaman M.T., Bihl F., Khatri A., John M., Mallal S., Marincola F.M., Walker B.D., Sette A., Heckerman D., Korber B.T., and Brander C. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur. J. Immunol. 37 (2007) 2419
20. Goulder P.J., Edwards A., Phillips R.E., and McMichael A.J. Identification of a novel HLA-B*3501-restricted cytotoxic T lymphocyte epitope using overlapping peptides. Aids 11 (1997) 930
21. Harrer T., Harrer E., Barbosa P., Kaufmann F., Wagner R., Bruggemann S., Kalden J.R., Feinberg M., Johnson R.P., Buchbinder S., and Walker B.D. Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual. J. Immunol. 161 (1998) 4875
22. Harrop R., Drury N., Shingler W., Chikoti P., Redchenko I., Carroll M.W., Kingsman S.M., Naylor S., Griffiths R., Steven N., and Hawkins R.E. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol. Immunother. 57 (2008) 977
23. Hendel H., Caillat-Zucman S., Lebuanec H., Carrington M., O'Brien S., Andrieu J.M., Schachter F., Zagury D., Rappaport J., Winkler C., Nelson G.W., and Zagury J.F. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J. Immunol. 162 (1999) 6942
24. Imami N., Hardy G.A., Nelson M.R., Morris-Jones S., Al-Shahi R., Antonopoulos C., Gazzard B., and Gotch F.M. Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy. Clin. Exp. Immunol. 118 (1999) 78
25. Imami N., Hardy G., Burton C., Pires A., Pido-Lopez J., Moss R., Gazzard B., and Gotch F. Immune responses and reconstitution in HIV-1 infected individuals: impact of anti-retroviral therapy, cytokines and therapeutic vaccination. Immunol. Lett. 79 (2001) 63
26. Imami N., Pires A., Hardy G., Wilson J., Gazzard B., and Gotch F. A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection. J. Virol. 76 (2002) 9011
27. Jin X., Roberts C.G., Nixon D.F., Safrit J.T., Zhang L.Q., Huang Y.X., Bhardwaj N., Jesdale B., DeGroot A.S., and Koup R.A. Identification of subdominant cytotoxic T lymphocyte epitopes encoded by autologous HIV type 1 sequences, using dendritic cell stimulation and computer-driven algorithm. AIDS Res. Hum. Retrovir. 16 (2000) 67
28. Jin X., Gao X., Ramanathan Jr. M., Deschenes G.R., Nelson G.W., O'Brien S.J., Goedert J.J., Ho D.D., O'Brien T.R., and Carrington M. Human immunodeficiency virus type 1 (HIV-1)-specific CD8+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes. J. Virol. 76 (2002) 12603
29. Kaslow R.A., Duquesnoy R., VanRaden M., Kingsley L., Marrari M., Friedman H., Su S., Saah A.J., Detels R., Phair J., et al. A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study. Lancet 335 (1990) 927
30. Kiepiela P., Leslie A.J., Honeyborne I., Ramduth D., Thobakgale C., Chetty S., Rathnavalu P., Moore C., Pfafferott K.J., Hilton L., Zimbwa P., Moore S., Allen T., Brander C., Addo M.M., Altfeld M., James I., Mallal S., Bunce M., Barber L.D., Szinger J., Day C., Klenerman P., Mullins J., Korber B., Coovadia H.M., Walker B.D., and Goulder P.J. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432 (2004) 769
31. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., Reddy S., de Pierres C., Mncube Z., Mkhwanazi N., Bishop K., van der Stok M., Nair K., Khan N., Crawford H., Payne R., Leslie A., Prado J., Prendergast A., Frater J., McCarthy N., Brander C., Learn G.H., Nickle D., Rousseau C., Coovadia H., Mullins J.I., Heckerman D., Walker B.D., and Goulder P. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13 (2007) 46 Electronic publication 2006 Dec 17
32. Klein M.R., Smith S.M., Hammond A.S., Ogg G.S., King A.S., Vekemans J., Jaye A., Lukey P.T., and McAdam K.P. HLA-B*35-restricted CD8 T cell epitopes in the antigen 85 complex of Mycobacterium tuberculosis. J. Infect. Dis. 183 (2001) 928
33. Lichterfeld M., Yu X.G., Mui S.K., Williams K.L., Trocha A., Brockman M.A., Allgaier R.L., Waring M.T., Koibuchi T., Johnston M.N., Cohen D., Allen T.M., Rosenberg E.S., Walker B.D., and Altfeld M. Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J. Virol. 81 (2007) 4199
34. Malek T.R. The biology of interleukin-2. Annu. Rev. Immunol. 26 (2008) 453
35. Marsh S.G.E., Parham P., and Barber L.D. The HLA Factsbook (2000), Academic Press, San Diego
36. McMichael A.J. HIV Vaccines. Annu. Rev. Immunol. 24 (2006) 227
37. McMichael A.J., and Walker B.D. Cytotoxic T lymphocytes epitopes: implications for HIV vaccine. AIDS 8S (1994) S155
38. Migueles S.A., Laborico A.C., Shupert W.L., Sabbaghian M.S., Rabin R., Hallahan C.W., Van Baarle D., Kostense S., Miedema F., McLaughlin M., Ehler L., Metcalf J., Liu S., and Connors M. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3 (2002) 1061 Electronic publication 2002 oct. 7
39. Nielsen M., Lundegaard C., Worning P., Lauemoller S.L., Lamberth K., Buus S., Brunak S., and Lund O. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12 (2003) 1007
40. Qazi N., Westrop S., Gotch F., Gazzard B., and Imami N. Broad HIV-1-specific T-cell responses are maintained in true long-term non-progressors. HIV Med. 8 s1 (2007) 17
41. Rosenberg E.S., Billingsley J.M., Caliendo A.M., Boswell S.L., Sax P.E., Kalams S.A., and Walker B.D. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278 (1997) 1447
42. Sabbaj S., Bansal A., Ritter G.D., Perkins C., Edwards B.H., Gough E., Tang J., Szinger J.J., Korber B., Wilson C.M., Kaslow R.A., Mulligan M.J., and Goepfert P.A. Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities. J. Acquir. Immune Defic. Syndr. 33 (2003) 426
43. Sallusto F., Lenig D., Forster R., Lipp M., and Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401 (1999) 708
44. Stebbing J., Bower M., Mandalia S., Nelson M., and Gazzard B. Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality. Clin. Exp. Immunol. 145 (2006) 271
45. Trautmann L., Rimbert M., Echasserieau K., Saulquin X., Neveu B., Dechanet J., Cerundolo V., and Bonneville M. Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses. J. Immunol. 175 (2005) 6123
46. Valitutti S., Muller S., Dessing M., and Lanzavecchia A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 183 (1996) 1917
47. van Stipdonk M.J., Lemmens E.E., and Schoenberger S.P. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat. Immunol. 2 (2001) 423
48. Vezys V., Masopust D., Kemball C.C., Barber D.L., O'Mara L.A., Larsen C.P., Pearson T.C., Ahmed R., and Lukacher A.E. Continuous recruitment of naive T cells contributes to heterogeneity of antiviral CD8 T cells during persistent infection. J. Exp. Med. 203 (2006) 2263
49. Viola A., and Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 273 (1996) 104
50. Watson J., Mochizuki D., and Gillis S. Purification of murine helper T cell-replacing factors. Prog. Clin. Biol. Res. 66 (1981) 513 Pt A
51. Wilson J.D., Imami N., Watkins A., Gill J., Hay P., Gazzard B., Westby M., and Gotch F.M. Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J. Infect. Dis. 182 (2000) 792 Electronic publicaton 2000 Aug 17
52. Yu X.G., Addo M.M., Rosenberg E.S., Rodriguez W.R., Lee P.K., Fitzpatrick C.A., Johnston M.N., Strick D., Goulder P.J., Walker B.D., and Altfeld M. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J. Virol. 76 (2002) 8690